阿昔洛韦或伐昔洛韦抑制单纯疱疹病毒 2 型治疗不会在 HIV-1/HSV-2 双重感染人群中选择出特定的 HIV-1 耐药性。
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
机构信息
Department of Global Health, University of Washington, Seattle, Washington, USA.
出版信息
J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.
Abstract
Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.
摘要
最近的体外研究表明，阿昔洛韦可能直接抑制 HIV-1 的复制，并可能选择具有特定 HIV-1 逆转录酶突变（V75I）的药物，同时丧失抗 HIV-1 的作用。我们在来自博茨瓦纳、肯尼亚、秘鲁和美国的 168 名接受每日阿昔洛韦或伐昔洛韦治疗 8 周至 24 个月的 HIV-1 感染者的血浆中，检测了逆转录酶密码子 75 处的 HIV-1 基因型耐药性。未检测到 V75I 病例（95%置信区间，0%-2.2%）。这些前瞻性体内研究表明，标准剂量的阿昔洛韦或伐昔洛韦不会选择出 HIV-1 耐药性。
相似文献
1
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.
2
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.
3
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
N Engl J Med. 2007 Feb 22;356(8):790-9. doi: 10.1056/NEJMoa062607.
4
HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
AIDS. 2009 Feb 20;23(4):479-83. doi: 10.1097/QAD.0b013e328326ca62.
5
High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.
6
Time to refocus on HSV interventions for HIV prevention?
J Infect Dis. 2011 Dec 15;204(12):1822-6. doi: 10.1093/infdis/jir653. Epub 2011 Oct 12.
7
Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
J Clin Microbiol. 2010 Oct;48(10):3496-503. doi: 10.1128/JCM.01263-10. Epub 2010 Aug 11.
8
The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Int J STD AIDS. 2015 Jul;26(8):574-81. doi: 10.1177/0956462414546504. Epub 2014 Aug 21.
9
A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14.
10
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
J Infect Dis. 2010 Sep 1;202(5):734-8. doi: 10.1086/655662.
引用本文的文献
1
Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Clin Infect Dis. 2015 Jun 1;60(11):1708-14. doi: 10.1093/cid/civ172. Epub 2015 Mar 3.
2
Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.
BMC Infect Dis. 2013 Oct 28;13:502. doi: 10.1186/1471-2334-13-502.
3
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.
4
Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.
AIDS Res Hum Retroviruses. 2013 Jan;29(1):164-71. doi: 10.1089/AID.2012.0206.
5
Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
AIDS Res Hum Retroviruses. 2013 Jan;29(1):94-8. doi: 10.1089/AID.2012.0071. Epub 2012 Sep 4.
6
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
PLoS One. 2012;7(6):e38622. doi: 10.1371/journal.pone.0038622. Epub 2012 Jun 12.
7
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
Lancet Infect Dis. 2012 Jun;12(6):441-8. doi: 10.1016/S1473-3099(12)70037-3. Epub 2012 Mar 19.
8
Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.
Curr HIV Res. 2012 Apr;10(3):228-37. doi: 10.2174/157016212800618156.
9
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Antimicrob Agents Chemother. 2012 May;56(5):2604-11. doi: 10.1128/AAC.05986-11. Epub 2012 Feb 6.
10
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
J Infect Dis. 2012 Feb 1;205(3):366-75. doi: 10.1093/infdis/jir766. Epub 2011 Dec 6.
本文引用的文献
1
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.
2
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.
3
HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
AIDS. 2009 Feb 20;23(4):479-83. doi: 10.1097/QAD.0b013e328326ca62.
4
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
AIDS. 2009 Feb 20;23(4):461-9. doi: 10.1097/QAD.0b013e32831db217.
5
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
J Infect Dis. 2008 Dec 15;198(12):1804-8. doi: 10.1086/593214.
6
The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
J Biol Chem. 2008 Nov 14;283(46):31289-93. doi: 10.1074/jbc.C800188200. Epub 2008 Sep 24.
7
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Cell Host Microbe. 2008 Sep 11;4(3):260-270. doi: 10.1016/j.chom.2008.07.008.
8
Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.
J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):77-83. doi: 10.1097/QAI.0b013e3181831832.
9
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
J Infect Dis. 2007 Nov 15;196(10):1500-8. doi: 10.1086/522523. Epub 2007 Oct 31.
10
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
N Engl J Med. 2007 Feb 22;356(8):790-9. doi: 10.1056/NEJMoa062607.
Zotero 插件